R&D News | pharmaphorum

News

Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for obstructive sleep apnoea.

News

Non-profit DNDi has licensed a dengue therapy from India's SII, paving the way for a phase 3 trial in Malaysia, Thailand, and Brazil.

News

Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to abandon BL117 for glaucoma.

News

Roche has scrapped two drugs for Huntington's disease – tominersen and RG6496 – after seeing disappointing results in clinical trials.

News

Keenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet.

News

GSK's alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.